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LogPAbstract Novel Triclosan mimic diphenyl ether derivatives 4a–k were designed and synthesized
with lipophilicity considerably lesser than that of Triclosan. The binding mode of the compounds
at the active site of enoyl-ACP reductase was analysed using docking method. The syntheses were
carried out with one-pot reductive amination reaction and were characterized by spectral tech-
niques. The synthesized compounds were evaluated for their in vitro antitubercular activity against
Mycobacterium tuberculosis H37Rv strain by Microplate Alamar Blue assay. Compounds 4h and 4j
were the most active compounds with MIC equal to 25 lg/mL against M. tuberculosis H37Rv
strain. All compounds were also examined for their cytotoxic potential against VERO and HepG2
cell lines and were safe even at 300 lg/mL. LogP of all the synthesized compounds was evaluated by
RPHPLC and was significantly lesser than Triclosan.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis is a significant medical problem worldwide, par-
ticularly in the developing world, where up to 80% of the pop-
ulation are thought to be infected by the bacterium
Mycobacterium tuberculosis in either latent or active form. Itis responsible for nearly 3 million deaths worldwide every year
(Bloom and Murray, 1992, Organisation, 2013). While tuber-
culosis is treatable through antibiotic regimes, the currently
used frontline antimycobacterial drugs, isonicotinylhydrazine
(INH) and rifampicin (RMP), have been used in the treatment
of tuberculosis for at least 50 years. Long treatment times tend
to lead to poor patient treatment compliance, which coupled
with the lack of successful development of new classes of
antimycobacterial drugs has led to the emergence of drug
resistant strains of M. tuberculosis. These include multidrug
resistant TB (MDR-TB), extensively drug resistant TB
(XDR-TB) and, more recently, totally drug resistant TB
(TDR-TB) which is resistant to all currently available antibi-
otics. Increase in the incidence of TB in the recent years hashemistry
2 T.A. Cinu et al.also been attributed to the co-infection with HIV (El Sayed
et al., 2000). This underlines the urgent need to develop new
classes of antimycobacterial drugs.
To address the problems of ever increasing resistance, seri-
ous side effects of some anti-TB drugs, long term treatment,
incompatibility of antiretroviral therapies for current TB regi-
men, research activities to develop novel anti-TB agents with
stronger efficacy have become an urgent priority. Many studies
targeting the mycobacterial cell wall and particularly the
biosynthesis of mycolic acid have been reported. InhA [also
known as Enoyl Acyl Carrier protein Reductase (Mtb ENR)]
is an essential enzyme of mycolic acid biosynthesis pathway.
This pathway is involved in the synthesis of type II fatty acids
required for the formation of the mycobacterial cell wall and
therefore, considered as a good target (Bloch, 1977;
Marrakchi et al., 2008). The major advantage of this target
is that, it is present in the Mycobacterium but is absent in
human. Moreover, InhA has already been known as the
molecular target of the frontline antitubercular drugs isoniazid
and ethionamide (ETA) (Banerjee et al., 1994; Wang et al.,
2007). Well-known local antibacterial agent Triclosan (1) has
been reported to be a specific InhA inhibitor (Levy et al.,
1999). Unfortunately, Triclosan has the disadvantage such as
higher lipophilicity and moderate MIC (12.5 lg/ml) (Dann
and Hontela, 2011). Hence major attention has been put
forward to develop a druggable Triclosan analogue with
improved antitubercular activity. The study reported herein
concerns our efforts to optimize the Triclosan scaffold to
decrease its lipophilicity without compromising the antituber-
cular activity and cytotoxicity. We have also attempted the
structure based drug design technique to explore the structural
alternates at the position 4 of ring-A of Triclosan to sustain the
molecular interactions of a typical InhA inhibitor at the
receptor binding pocket.2. Materials and methods
2.1. Molecular modeling
A library of Triclosan (1) analogues was prepared considering
Lipinski’s drug-like parameters [molecular weight 6 500,
CLogP 6 5, hydrogen bond donors 6 5 and hydrogen bond
acceptors 6 10]. Structures of designed diphenyl ethers were
drawn and converted to 3D structures. Generation of ioniza-
tion state (through Epik) of the ligands was done using
Ligprep tool of Schrodinger-2011. OPLS-2005 force field was
used for the energy minimization of 3D structures of the
ligands. The X-ray structure of M. tuberculosis ENR
(pdb 1P45) was used in all the docking experiments. The InhA
protein was optimized through Protein preparation wizard of
Schrodinger-2011. Protein was pre-processed by assigning
bond order, adding hydrogens and treating disulfide. Water
molecules within 5 A˚ of the binding site were removed. Hydro-
gen bond was assigned by exhaustive sampling and energy was
minimized to RMSD 0.30 A˚ by OPLS-2005. Receptor grid was
generated around the co-crystallized ligand (Triclosan) in
Schrodinger-2011 suit by using default parameters. Ligand
was excluded from the protein, and it was confined to the
enclosing box at the centroid. The grid was generated to fit
the ligands similar in size to Triclosan. Flexible docking study
was conducted with standard precision (SP) (Friesner et al.,Please cite this article in press as: Cinu, T.A. et al., Design, synthesis and evaluation
(2015), http://dx.doi.org/10.1016/j.arabjc.2015.09.0032004; Halgren et al., 2004). Epik state penalty was added to
the docking score. Docking was limited to the ligands having
<300 atoms and <50 rotable bonds. Van der Waal radii of
the ligand atoms were scaled to 0.8 and the partial charge cut-
off was kept less than 0.15. The position of ligand was kept at
the center of a 10 A˚ docking sphere. Default settings were used
in Glide for all dockings. At the beginning, co-crystallized
ligand (Triclosan) was extracted from the optimized protein
and redocked to probe the RMSD and docking parameters.
Then all the compounds were docked with the Mtb InhA pro-
tein at the Triclosan binding site. Then all ligand docking
results from SP docking were studied.
2.2. Synthesis
All the chemicals used as starting materials and catalysts in
this study were purchased from Aldrich Chemical Co., India,
Spectrochem Ltd. India, TCI Chemicals, India, and Himedia,
India. All the solvents used were obtained from S.D. Fine
Chemicals Ltd, India, and Merck, India. Column chromatog-
raphy was carried out on 100–200 mesh silica gel. Progress of
the reactions was monitored by TLC using Aluminum backed
sheets of silica gel 60 F24 (Merck, India). Melting points were
recorded with a laboratory melting point apparatus and are
uncorrected. 1H NMR and 13C NMR spectra were recorded
on NMR Spectrometer (AV400-400 MHz High Resolution
Multinuclear FT-NMR Spectrometer, Bruker, USA) using
DMSO-d6 as the solvent. Mass spectroscopy was performed
using LC-MS (Q-TOF LC/MS, Agilent 6520 series, USA)
and GC–MS (GCMS-QP5050A, Shimadzu, Japan). IR spec-
trum was obtained using FT IR Spectrophotometer (IR
Affinity-1, Shimadzu, Japan) using KBr pellets.
2.2.1. 3-Methoxy-4-phenoxybenzaldehyde (2)
To the stirred solution of vanillin (5 g, 32.89 mmol) in anhy-
drous dichloromethane (60 mL), activated molecular sieves
(4 A˚, 2.5 g), phenylboronic acid (6.01 g, 49.33 mmol), copper
(II) acetate (8.96 g, 49.33 mmol) and anhydrous pyridine
(5.19 g, 64.78 mmol) were added successively. The resulting
suspension was stirred at 25–27 C for 72 h. Progress of the
reaction was monitored by TLC, using hexane:ethyl acetate
(8:2) as mobile phase. After the completion of reaction
(72 h), the reaction mixture was diluted with dichloromethane
(40 mL) and filtered under vacuum. The filtrate was washed
with dilute aqueous hydrochloric acid solution (2 M, 50 mL),
followed by water (50 mL), dried over anhydrous MgSO4
and evaporated under vacuum. The crude compound obtained
was purified by column chromatography over silica 100–200
with hexane:ethyl acetate (8:2) as the mobile phase to afford
the target compound.
Yield = 5 g (67%); mp = 40–42 C; Rf = 0.83 (hexane:
ethyl acetate = 8:2); kmax = 275.2 nm (MeOH).
2.2.2. 3-Hydroxy-4-phenoxybenzaldehyde (3)
To the solution of compound 4 (3 g, 13.16 mmol) in glacial
acetic acid (50 mL), HBr (48%v/v, 12 mL) was added and
the solution was refluxed at 110–112 C for 24 h. Progress of
the reaction was monitored by TLC, using hexane:ethyl acet-
ate (8:2) as mobile phase. The reaction mixture was cooled,
poured into water and extracted with ethyl acetate
(3  50 mL). The organic layers were combined and washedof antitubercular activity of Triclosan analogues. Arabian Journal of Chemistry
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MgSO4 and evaporated under vacuum. The crude product
obtained was purified by column chromatography over silica
100–200 with hexane:ethyl acetate (8:2) as the mobile phase
to afford the target compound.
Yield = 0.226 g (60%); mp = 82–84 C; Rf = 0.59 (hex-
ane:ethyl acetate = 6:4); kmax = 275 nm (MeOH); IR (KBr,
cm1) = 3452, 3057, 1680, 1527, 1483, 1440, 1245, 1132; 1H
NMR (400 MHz, DMSO-d6): 10.08 (s, 1H), 9.85 (s, 1H),
7.42 (d, J= 1.6 Hz, 1H), 7.39–7.35 (m, 3H), 7.14–7.10 (m,
1H), 7.01–7.26 (d, J= 8 Hz, 1H), 6.98–6.96 (td, J= 8 Hz
and 1.6 Hz, 2H); LCMS (+ESI, m/z): 215.069 (M+ H).
2.2.3. General procedure for the synthesis of compounds 4a–k
To the stirred solution of amine (1.12 mmol) in Dichlor-
oethane (5 mL), compound 2 (0.2 g, 0.93 mmol), NaBH3CN
(0.058 g, 0.93 mmol) and glacial acetic acid (2 drops) were
added and stirring was continued at room temperature for
12 h. Progress of the reaction was monitored by TLC, using
chloroform:methanol (9:1) as mobile phase. After completion
of reaction, the solvent was evaporated; water was added,
and extracted with ethyl acetate (3  20 mL). The organic lay-
ers were combined and washed with sodium bicarbonate solu-
tion, dried over anhydrous MgSO4 and evaporated under
vacuum. The crude product obtained was purified by column
chromatography over silica 100–200 with chloroform:metha-
nol (9:1) as the mobile phase to afford the target compound.2.2.3.1. 5-Butylaminomethyl-2-phenoxy-phenol (4a).
Yield = 0.160 g (63%); mp = 104–106 C; Rf = 0.41 (chloro-
form:methanol = 9:1); kmax = 276 nm (MeOH); IR (KBr,
cm1) = 3525, 3305, 2945, 2846, 1597, 1514, 1487, 1292,
1246, 1211, 1159; 1H NMR (400 MHz, DMSO-d6): 9.39 (s,
1H), 7.28 (t, J= 7.8 Hz, 2H), 7.00–6.95(m, 2H), 6.88(d,
J= 8 Hz, 1H), 6.81(d, J= 8 Hz, 2H), 6.76(d, J= 8 Hz,
1H), 5.88(s, 1H),1.47–1.27(m, 6H), 0.86(t, J= 12 Hz, 3H),
13C NMR (100.62 MHz, DMSO-d6): 13.92, 19.95, 29.87,
31.49, 39.48, 45.65, 48.32, 52.51, 116.75, 119.04, 121.45,
138.14, 140.86, 149.02, 158.16; LCMS(+APCI, m/z): 272.17
(M+H)+.
2.2.3.2. 5-(tert-Butylamino-methyl)-2-phenoxy-phenol (4b).
Yield = 0.180 g (71%); mp = 94–96 C; Rf = 0.45 (chloro-
form:methanol = 9:1); kmax = 276 nm (MeOH); IR (KBr,
cm1) = 3348, 2964, 2873, 1589, 1487, 1496, 1298, 1224,
1161, 1H NMR (400 MHz, DMSO-d6): 9.40 (s, 1H), 7.28 (t,
J= 8 Hz, 2H), 7.00–6.98(m, 2H), 6.88(d, J= 8 Hz, 1H),
6.81(d, J= 8 Hz, 2H), 6.77(d, J= 7.6 Hz, 1H), 5.82(s, 1H),
3.61(s, 2H),1.10(s, 9H); 13C NMR (100.62 MHz, DMSO-d6):
39.48, 115.83, 121.61, 129.45, 148.99;GCMS (EI, m/z) 269
(M  2)+.
2.2.3.3. 5-Allylaminomethyl-2-phenoxy-phenol (4c).
Yield = 0.165 g (69%); mp = 84–86 C; Rf = 0.37 (chloro-
form:methanol = 9:1); kmax = 276 nm (MeOH); IR (KBr,
cm1) = 3388, 3288, 2929, 2858, 1583, 1494, 1458, 1261,
1213, 1161; 1H NMR (400 MHz, DMSO-d6): 9.42 (s, 1H),
7.28 (t, J= 7.8 Hz, 2H), 7.00–6.95(m, 2H), 6.88(d, J= 8 Hz,
1H), 6.82(d, J= 8 Hz, 2H), 6.75(d, J= 7.2 Hz, 1H), 5.91–
5.82(m, 1H), 5.19–5.14(dd, J= 17.2 Hz and J= 1.6 Hz,
1H), 5.06(d, J= 10.4 Hz, 1H), 3.59(s, 2H), 3.14(d,Please cite this article in press as: Cinu, T.A. et al., Design, synthesis and evaluation
(2015), http://dx.doi.org/10.1016/j.arabjc.2015.09.003J= 5.6 Hz, 2H), 2.50(s, 1H); 13C NMR (100.62 MHz,
DMSO-d6): 39.70, 50.89, 51.74, 115.90, 116.73, 117.89,
119.02, 126.63, 132.15, 138.29, 140.82, 158.17; LCMS(+APCI,
m/z): 256.08(M+H)+.
2.2.3.4. 2-Phenoxy-5-pyrrolidin-1-ylmethyl-phenol (4d).
Yield = 0.120 g (48%); mp = 102–104 C; Rf = 0.37 (chloro-
form:methanol = 9:1); kmax = 278 nm (MeOH); IR (KBr,
cm1) = 3365, 2958, 1517, 1485, 1456, 1296, 1244, 1220,
1161; 1H NMR(400 MHz, DMSO-d6): 9.42 (s, 1H), 7.29 (t,
J= 7.6 Hz, 1H), 6.99(t, J= 7.2 Hz, 1H), 6.93(s, 1H), 6.87(d,
J= 8 Hz, 1H), 6.82(d, J= 8 Hz, 3H), 6.73(d, J= 7.6 Hz,
1H), 3.48(s, 2H), 2.42(s, 4H), 1.69(s, 4H); 13C NMR
(100.62 MHz, DMSO-d6): 23.11, 39.51, 53.49, 59.18, 141.04,
149.00, 158.10; GCMS(EI, m/z) 269 (M)+.
2.2.3.5. 2-Phenoxy-5-piperidin-1-ylmethyl-phenol (4e).
Yield = 0.230 g (87%); mp = 110–112 C; Rf = 0.73 (chloro-
form:methanol = 9:1); kmax = 276 nm (MeOH); IR (KBr,
cm1) = 3396, 2939, 1519, 1485, 1460, 1286, 1228, 1157; 1H
NMR (400 MHz, DMSO-d6): 9.44 (s, 1H), 7.29 (t, J= 8 Hz,
2H), 6.99(t, J= 7.4 Hz, 1H), 6.92(d, J= 1.2 Hz, 1H), 6.87
(d, J= 8.4 Hz, 1H), 6.82(d, J= 7.6 Hz, 2H), 6.72(d,
J= 7.6 Hz,1H), 3.34(s, 2H), 2.3(s, 4H), 1.51–1.39(m, 6H);
13C NMR (100.62 MHz, DMSO-d6): 24.02, 39.49, 50.98,
53.91, 62.44, 116.41, 117.26, 119.74, 121.68, 129.48, 136.09,
141.05, 149.01, 158.09; GCMS(EI, m/z) 283 (M)+.
2.2.3.6. 1-(3-Hydroxy-4-phenoxy-benzyl)-piperidin-4-ol (4f).
Yield = 0.220 g (79%); mp = 74–76 C; Rf = 0.71 (chloro-
form:methanol = 8:2); kmax = 278 nm (MeOH); IR (KBr,
cm1) = 3419, 3305, 2949, 2850, 2816, 1589, 1487, 1296,
1244, 1161; 1H NMR(400 MHz, DMSO-d6): 9.55 (s, 1H),
7.30 (t, J= 7.8 Hz, 2H), 7.03–6.98(m, 2H), 6.91(d,
J= 8 Hz,1H), 6.84 (d, J= 8 Hz, 2H), 6.78(d,
J= 7.6 Hz,1H), 4.69 (s, 1H), 3.62 (s, 1H), 2.81(s, 2H), 2.28
(s, 2H), 1.91(s, 1H), 1.75(s, 2H), 1.46(d, J= 8.4 Hz, 2H); 13C
NMR (100.62 MHz, DMSO-d6): 21.03, 30.41, 33.32, 39.50,
40.13, 45.30, 50.15, 60.76, 116.20, 118.03, 121.40, 129.52,
141.86, 149.04, 157.88; GCMS(EI, m/z): 298 (M  1)+.
2.2.3.7. 5-(4-Methyl-piperidin-1-ylmethyl)-2-phenoxy-phenol
(4g). Yield = 0.225 g (81%); mp = 128–130 C; Rf = 0.82
(chloroform:methanol = 9:1); kmax = 278 nm (MeOH); IR
(KBr, cm1) = 3425, 2947, 2922, 1519, 1487, 1452, 1282,
1249, 1224, 1157; 1H NMR(400 MHz, DMSO-d6): 9.44 (s,
1H), 7.28 (t, J= 7.8 Hz, 2H), 6.99(t, J= 7.4 Hz, 1H), 6.92
(s, 1H), 6.87(d, J= 8 Hz, 1H), 6.82 (d, J= 7.6 Hz, 2H),
6.71(d, J= 8 Hz,1H), 3.34(s, 2H), 2.77–2.5(m, 4H), 1.321–
1.230 (m, 1H), 1.171–1.089(m, 4H); 13C NMR (100.62 MHz,
DMSO-d6): 21.82, 28.61, 32.14, 34.00, 39.5, 5083, 62.50,
116,00, 119.72, 121.46, 140.92, 149.00, 158.19; GCMS(EI, m/
z) 297 (M)+.
2.2.3.8. 5-(4-Aminomethyl-piperidin-1-ylmethyl)-2-phenoxy-
phenol (4h). Yield = 0.220 g (79%); Rf = 0.71 (chloroform:
methanol = 8:2); kmax = 278 nm (MeOH); IR (KBr, cm1)
3622, 3589, 3452, 3425, 3398, 2933, 2368, 1589, 1519, 1467,
1300, 1220, 1181; 1H NMR(400 MHz, DMSO-d6): 9.55 (s,
1H), 7.29 (t, J= 7.8 Hz, 2H), 7.01–6.95(m, 2H), 6.88 (d,
J= 8 Hz,1H), 6.82 (d, J= 8 Hz, 2H), 6.71(d, J= 8 Hz,1H),
3.42(s, 2H), 2.72–2.63(m, 4H), 1.88(s, 2H), 1.77–1.69(m, 2H),of antitubercular activity of Triclosan analogues. Arabian Journal of Chemistry
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29.62, 38.86, 39.49, 43.87, 49.79, 50.26, 52.57, 61.89, 115.99,
117.40, 119.74, 121.48, 129.48, 135.79, 141.18, 149.08, 158.07;
LCMS (+APCI, m/z): 313.25 (M+ H)+.
2.2.3.9. 5-Morpholine-4-ylmethyl-2-phenoxy-phenol (4i).
Yield = 0.182 g (68%); mp = 80–82 C; Rf = o.87 (chloro-
form:methanol = 9:1); kmax = 276 nm (MeOH); IR (KBr,
cm1) = 3363, 3057, 1519, 1487, 1452, 1265,1220, 1159; 1H
NMR (400 MHz, DMSO-d6): 9.47 (s, 1H), 7.29 (t,
J= 7.6 Hz, 2H), 6.99(t, J= 7.2 Hz, 1H), 6.94(s, 1H), 6.89
(d, J= 8 Hz, 1H), 6.82 (d, J= 8 Hz, 2H), 6.73(d,
J= 7.6 Hz, 1H), 3.58(s, 4H), 3.35(s, 2H), 2.35 (s, 4H); 13C
NMR (100.62 MHz, DMSO-d6): 38.86, 39.07, 39.28, 40.11,
53.16, 62.02, 66.21, 115.98, 117.47, 119.97, 121.51, 121.73,
129.49, 135.16, 141.26, 149.06,158.04; GCMS(EI, m/z)
285 (M)+.
2.2.3.10. 2-Phenoxy-5-thiomorpholin-4-ylmethyl-phenol (4j).
Yield = 0.215 g (77%); mp = 124–126 C; Rf = 0.82
(chloroform:methanol = 9:1); kmax = 278 nm (MeOH); IR
(KBr, cm1) = 3360, 2929, 2821, 1519, 1487, 1288, 1253,
1163; 1H NMR(400 MHz, DMSO-d6): 9.48 (s, 1H), 7.29 (t,
J= 7.6 Hz, 2H), 7.00(t, J= 7.4 Hz, 1H), 6.92(s, 1H), 6.88(d,
J= 8 Hz, 1H), 6.82(d, J= 8.4 Hz, 2H), 6.72(d,
J= 7.6 Hz,1H), 3.40(s, 4H), 3.34(s, 2H), 2.50(s, 4H); 13C
NMR (100.62 MHz, DMSO-d6): 27.18, 39.46, 54.40, 62.15,
117.34, 119.85, 121.76, 129.49, 135.35, 141.28, 149.02, 158.02,
GCMS(EI, m/z) 301 (M)+.
2.2.3.11. 5-(4-Methyl-piperazin-1-ylmethyl)-2-phenoxy-phenol
(4k). Yield = 0.160 g (57%); mp = 128–130 C; Rf = 0.7
(chloroform:methanol = 8:2); kmax = 278 nm (MeOH); IR
(KBr, cm1) = 3425, 2951, 2819, 1500, 1487, 1292, 1215,
1174; 1H NMR(400 MHz, DMSO-d6): 9.50 (s, 1H), 7.29 (t,
J= 7.8 Hz, 2H), 6.99(t, J= 7.2 Hz, 1H), 6.91(s, 1H), 6.88(d,
J= 8 Hz, 1H), 6.82(d, J= 8.4 Hz, 2H), 6.72(d,
J= 8 Hz,1H), 3.62(s, 1H), 2.33(s, 8H), 2.17–2.08(m, 3H);
13C NMR (100.62 MHz, DMSO-d6): 39.39, 45.66, 49.92,
52.45, 54.66, 61.61, 115.99, 148.97, 158.03; GCMS(EI, m/z)
298 (M)+.
2.3. Biological activity
2.3.1. Anti-tubercular activity
Synthesized compounds were screened against M. tuberculosis
H37Rv using Micro plate Alamar Blue Assay (MABA)
(Leonard et al., 2008; Ryan et al., 1995). Frozen stock culture
suspension of M. tuberculosis H37Rv (ATTCC 27294) from
Lowenstein–Jensen slants in complete 7H9 broth was vor-
texed, adjusted to a turbidity equivalent to that of a 1 McFar-
land standard (3  108 cfu/mL). It was further diluted with
media-I (Difco Middlebrook 7H9, Bactocasitone, Difcoglyc-
erol and OADC) to a concentration of 2  105 cfu/mL and
used as inoculum in the MABA assay. Test samples and stan-
dard compounds (Isoniazid and Rifampicin) were dissolved in
DMSO and sterilized by filtering through syringe driven filters
(0.22 lm, 13 mm, Himedia, India) to prepare stock solutions
of concentration 20,000 lg/mL. The stock solutions were
diluted serially with media-II (Middlebrook 7H9 broth, Bacto-
casitone, Difco polysorbate-80 and OADC) in a 96 deep wellPlease cite this article in press as: Cinu, T.A. et al., Design, synthesis and evaluation
(2015), http://dx.doi.org/10.1016/j.arabjc.2015.09.003plate to afford working solutions of 4 strength. Outer
perimeter wells of the 96 well plates were filled with sterile
deionized water to prevent dehydration in test wells during
incubation. Media-II (100 lL) was added to each well of the
96 well plate and twofold serial dilutions of the test com-
pounds was done directly on the plate by using a multi-
channel micropipette. Inoculum (100 lL, 2  105 cfu/mL)
was added to each well, yielding a final testing volume of
200 lL and the final drug concentrations tests were 3.125–
100 lg/mL. Isoniazid and Triclosan were used as standard
and DMSO as blank. Positive control (only inoculum) and
negative control (only media) were also applied in the plate
to minimize the error. Then the plate was sealed (breathseal)
and incubated at 37 C under aeration. On the seventh day
of incubation, 12.5 lL of 20% Tween-80 and 20 lL of Alamar
blue were added to each well of the plate and incubated for
another 24 h at 37 C. A change in color from blue to pink
was considered as the growth of the Mycobacterium at that
concentration of the drug. For better interpretation of the
results, the color was compared to the color present in the
growth control wells. The MICs were defined as the lowest
concentration of drug that inhibited bacterial growth.
2.3.2. In vitro cytotoxicity
Synthesized compounds were assessed for their in vitro safety
profile against Vero and HepG2 cells using MTT assay. The
cellular conversion of MTT [3-(4,5-dimethylthiazo-2-yl)-2,5-d
iphenyl-tetrazolium bromide] into a formazan product was
used to evaluate the cytotoxic effect of the synthesized com-
pounds against a mammalian Vero cell line from the kidney
of African Green monkey (Ammerman et al., 2008). Outer
perimeter wells of the 96 well plates were filled with sterile
deionized water to prevent dehydration in test wells during
incubation. Stock solution of test samples was diluted with
DMEM (without FBS) in a 96 deep well plate to afford work-
ing solutions of concentrations 300, 250, 200, 150, 100, 100 and
50 lg/mL. Final concentration of DMSO was kept 60.1%.
100 lL of test samples was added to each wells containing
monolayer of Vero cells (104 cells/well) in a 96-well plate.
The plate was incubated at 37 C with 5% of CO2 inside an
incubator. Positive control (only inoculum) and negative
control (only media) were also maintained in the plate. After
72 h of incubation, the supernatant was removed from the
wells. 50 lL of MTT reagent (2 mg/mL) was added to the wells
in dark and incubated at 37 C for 4 h. 50 lL of sterile DMSO
(filtered through 0.22 lm syringe filter) was added to each well
to dissolve the formazan crystals formed by the cells. The plate
was transferred to an incubator and kept at 37 C for 2 h.
Optical density (OD) of the wells was measured at 540 nm
using Elisa Reader. The CC50 values were determined using
a curve-fitting program.
2.3.3. In vitro hepatotoxicity
MTT assay against HepG2 cells was performed by following
the method described for in vitro cytotoxicity screening against
Vero cell line. In case of HepG2 cells, 5  103 cells/well was
added and MTT was added after 24 h of incubation.
Optical Density (OD) readings from each well were entered
into the equations shown below to determine % Cell Viability
and % Cell Inhibition.of antitubercular activity of Triclosan analogues. Arabian Journal of Chemistry
Antitubercular activity of Triclosan analogues 5% Cell Viability ¼ ðOptical Density of Test
=Optical Density of ControlÞ  100
% Cell Inhibition ¼ 100% Cell Viability2.4. Determination of logP
Reverse phase HPLC method was applied to determine the
logP (lipophilicity) of the compounds (Ong et al., 1996;
Poole and Poole, 2003). All the chromatographic runs were
conducted on HPLC (Shimadzu, Japan) at room temperature
using ODS-4 (Intersil ODS-4, 5 lm, 4.6  150 mm, GL
Science Inc., Japan) column and UV–Visible detector.
Numerical analysis and data processing were done using Lab
solution-2013 software. 3-Morpholinopropane-1-sulfonic acid
(MOPS, 4.18 g) was added to 900 mL octanol saturated MilliQ
water, and the volume was made up to 1 L. pH of the buffer
was adjusted to 7.4. A mixture of methanol (0.25%v/v octanol)
and buffer at the ratio of 60:40, 65:45 and 70:30, was used to
elute the test sample. 5 lL of the sample was injected, and flow
rate was kept at 1 mL/min. Signal was detected at kmax
270 nm. Sample run time was kept in between 15 min. and
1 h. Capacity factor (k0) was calculated for each run by using
the equation given below (Gocan et al., 2006).
k0 ¼ tR  t0=t0
where tR is the retention time of sample, t0 is the retention time
of blank (methanol). A graph was plotted by taking log k0
(y axis) and % methanol (3–4% concentrations) (x-axis).
The logarithm of k0 was extrapolated to a 0% concentration
of methanol in the graph. Log k0 at 0% methanol was calcu-
lated from the regression equation (R2 = 0.99) generated from
the graph to determine logP of the compounds.3. Results and discussion
3.1. Rationale of drug design and analysis of the docking results
Triclosan is highly lipophilic with log P value of 5.56. The
chlorine functionalities in the molecule contribute significantly
to the log P value. The objective of the present work is to
develop diphenyl ether derivatives with lower lipophilicity.
Chloro substitutions in ring-B of Triclosan are reported to
be involved in unfavorable steric interactions with the enzyme,
and their deletion from the scaffold increases the affinity 7-fold
(Sivaraman et al., 2004). Hence diphenyl ether derivatives
without chloro substitutions in ring-B and with hydrophilic
substituents at the 4th position of ring-A of diphenyl ether ring
(Fig. 1) were designed. These modifications aim to decrease the
inherent lipophilicity of Triclosan without compromising its
orientation and catalytic interactions at the receptor
(Mycobacterial Enoyl acyl carrier protein reductase [Mtb
ENR]) binding site.
Compounds that satisfied Lipinski’s parameter of drug-
likeness were docked against Mtb ENR. Molecular docking
results revealed that compounds 4a–k overlaid perfectly with
that of Triclosan (Figs. 2 and 3). Furthermore, docking studies
suggested the formation of hydrogen-bonding interactions
between phenolic –OH and ether oxygen of our compounds
with Tyr-158 and NAD-350 of Mtb ENR (Table 1). ThePlease cite this article in press as: Cinu, T.A. et al., Design, synthesis and evaluation
(2015), http://dx.doi.org/10.1016/j.arabjc.2015.09.003hydrogen bonding network was consistent throughout our
compounds, and this feature is reported to be a conserved
feature among all the InhA-inhibitor complexes, including
Triclosan (He et al., 2006). Hence the core features of
Triclosan, such as diphenyl ether ring and the phenolic –OH
in ring-A were kept intact in all the designed analogues.
Compounds with long chain aliphatic substituents (com-
pounds 4a, 4c and 4k) possessed low docking scores (Table 1),
indicating unfavorable orientations of the analogues at the
target binding site.3.2. Chemistry
The synthetic route employed is shown in Fig. 4. Lam-Cham
O-arylation of vanillin with phenyl boronic acid gave
3-methoxy-4-phenoxybenzaldehyde (compound 2) (Gillmore
et al., 2003; Tipparaju et al., 2008). HBr-AcOH assisted
O-demethylation (Chhibber et al., 2006) of compound 2
afforded 3-hydroxy-4-phenoxy benzaldehyde (Compound 3)
which was further appended with less lipophilic heterocycles
through reductive amination (Abdel-Magid and Mehrman,
2006) technique to give the desired compounds 4a–k.3.3. Biological evaluation
Compounds 4a–k was evaluated for antitubercular activity
against M. tuberculosis H37Rv using MABA technique
(Table 2). Safety profiles of the synthesized compounds are
also presented in Table 2. Compounds with n-butyl amine side
chain (4a) and allylamine side chain (4c) demonstrated poor
activity (MIC = 100 lg/mL), but when they were replaced
with tert-butyl amine substituent, further reduction in the
activity was observed (4b, MIC > 100 lg/mL). In general, it
was observed that the addition of long aliphatic chain sub-
stituents at A-ring of diphenyl ether scaffold results in dimin-
ished antitubercular activities. Introduction of pyrrolidine at
the 4th position of A-ring of diphenyl ether through a methy-
lene bridge resulted in improvement of activity (4d,
MIC = 50 lg/mL). However, this result was not sustained
with a piperidine substituent (4e, MIC = 100 lg/mL). Intro-
duction of a polar hydroxyl group at the 4th position of the
piperidine ring of compound 4e increased the antiTB activity
by twofold. But this activity was weakened with the incorpora-
tion of comparatively nonpolar methyl group in place of –OH
group of 4f. When the methyl group of piperidine in com-
pound 4g was replaced by a methyl amino group, excitingly,
there was improvement of activity (4hMIC= 25 lg/mL). This
increase in antitubercular activity was in line with the increased
lipophilicity (log P= 3.02) of compound 4h. When the piper-
idine substituent of compound 4e was replaced with morpho-
line, obtained compound 4i exhibited antiTB activity at
100 lg/mL. Introduction of thiomorpholine enhanced the
activity dramatically to 25 lg/mL without much increase in
the lipophilicity. But this promising antiTB activity of 4j was
not sustained with the introduction of N-methyl piperazine
which led to a drastic loss of activity. Overall SAR of the scaf-
fold suggests that there is a size limit requirement for sub-
stituents at the 4th position of A-ring of diphenyl ether
pharmacophore to attain the optimal activity. Although the
MIC results of our most active compounds (4h and 4j,of antitubercular activity of Triclosan analogues. Arabian Journal of Chemistry
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Figure 1 Chemical structure of Triclosan and its analogues (4a–k).
Figure 2 Compound 4h in the binding pocket of InhA.
Figure 3 Superimposition of compound 4a–k with Triclosan inside the InhA binding site.
6 T.A. Cinu et al.MIC= 25 lg/mL), were twofold less than the MIC of parent
Triclosan (MIC = 12.5 lg/mL), their log P values were found
to considerably lower than Triclosan (Table 2). Notably, allPlease cite this article in press as: Cinu, T.A. et al., Design, synthesis and evaluation
(2015), http://dx.doi.org/10.1016/j.arabjc.2015.09.003the synthesized Triclosan analogues displayed much lower tox-
icity in the MTT assay against epithelial cells (Vero) and hep-
atocytes (HepG2) than Triclosan.of antitubercular activity of Triclosan analogues. Arabian Journal of Chemistry
Table 1 Molecular docking and virtual screening results of compounds 4a–k.
Compounds Docking score H-bonding Interactions Lipinski’s parameter
Tyr-158 NAD-350
1 0
4a 6.79 p pp 1
4b 8.36 p pp 1
4c 6.23 p p 1
4d 8.41 p pp 1
4e 8.99 p pp 1
4f 9.38 p pp 1
4g 9.28 p pp 1
4h 9.01 p p 1
4i 8.52 p pp 1
4j 8.84 p pp 1
4k 7.23 p pp 1
p
= single H-bond interaction with NAD-350;
pp
= two H-bond interactions with NAD-350; 1 = satisfies Lipinski’s parameter, 0 = does
not satisfy Lipinski’s parameter.
OCH3
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HO O
OCH3
CHO
O
OH
CHO
O
OCH3
R
aReagents and conditions :(i).PhB(OH)  2, Cu(OAc)2, C5H5N, CH2Cl2, 25-27 oC, 72h; (ii).HBr (48%v/v), gla.AcOH, 110-112 oC, 24h; (iii) RH, NaBH 3CN, 
(CH2)2Cl2, Gla.AcOH, 25-27 oC,12h.
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Figure 4 Scheme for the synthesis of compounds 4a–k.
Table 2 In vitro antitubercular activity (MIC), cytotoxicity (CC50) and logP of Triclosan and its analogues 4a–k.
Compounds MIC (lg/mL)a CC50 (lg/mL)
b Selective Indexc logP
Vero HepG2
4a 100 >300 >300 – 1.85
4b >100 >300 >300 – 1.26
4c 100 >300 >300 – 1.71
4d 50 >300 >300 – 1.43
4e 100 >300 >300 – 1.73
4f 50 >300 >300 – 1.18
4g >100 >300 >300 – 2.36
4h 25 >300 >300 >10 3.02
4i 100 >300 >300 – 2.32
4j 25 >300 >300 >10 3.40
4k >100 >300 >300 – 1.90
1 12.5 5.56
INH 0.05 – – – –
a MIC =minimal drug concentration required to stop the growth of Mycobacterial tuberculosis H37Rv.
b CC50 = minimal drug concentration required for 50% death of viable cells.
c Selective index = CC50/MIC.
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8 T.A. Cinu et al.4. Conclusions
A series of Triclosan analogues has been designed, synthesized
and evaluated for antitubercular activity against M. tuberculo-
sis H37Rv. Most of the compounds showed weak to moderate
antitubercular activity. Most promising compounds 4j and 4h
exhibited MIC at 25 lg/mL againstM. tuberculosis H37Rv. All
of our synthesized compounds showed an excellent safety pro-
file and lesser lipophilicity than the Triclosan. However, more
experiments are needed to learn the structural requirements for
improvement of antitubercular activity of this scaffold. Fur-
ther studies are under progress.
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